At the time of writing, CorMedix Inc [CRMD] stock is trading at $4.76, up 1.06%. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The CRMD shares have gain 14.15% over the last week, with a monthly amount glided 31.49%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
On 8, April 2024, CorMedix Inc. Announces Commercial Agreement With ARC Dialysis, LLC. In a post published today on Yahoo Finance, CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing therapeutic products for life-threatening diseases and conditions, today announced that it has entered into a 5-year commercial supply contract with Florida-based dialysis provider, ARC Dialysis, LLC for the supply of DefenCath® (taurolidine and heparin).
From an analyst’s perspective:
CorMedix Inc [NASDAQ: CRMD] stock has seen the most recent analyst activity on August 10, 2023, when RBC Capital Mkts initiated its Outperform rating and assigned the stock a price target of $6. Previously, Needham started tracking the stock with Buy rating on February 17, 2021, and set its price target to $31. On September 29, 2020, JMP Securities initiated with a Mkt Outperform rating and assigned a price target of $22 on the stock. Truist started tracking the stock assigning a Buy rating and suggested a price target of $20 on September 21, 2020. B. Riley FBR initiated its recommendation with a Buy and recommended $48 as its price target on December 18, 2019. H.C. Wainwright reiterated a Buy rating for this stock on March 26, 2019, and upped its price target to $15. In a note dated December 06, 2018, ROTH Capital initiated an Buy rating and provided a target price of $6 on this stock.
For the past year, the stock price of CorMedix Inc fluctuated between $2.57 and $6.09. Currently, Wall Street analysts expect the stock to reach $9 within the next 12 months. CorMedix Inc [NASDAQ: CRMD] shares were valued at $4.76 at the most recent close of the market. An investor can expect a potential return of 89.08% based on the average CRMD price forecast.
Analyzing the CRMD fundamentals
According to CorMedix Inc [NASDAQ:CRMD], the company’s sales were 0.00M for trailing twelve months, which represents an -100.00% plunge. Gross Profit Margin for this corporation currently stands at -4.13% with Operating Profit Margin at -1403.21%, Pretax Profit Margin comes in at -1339.78%, and Net Profit Margin reading is 13519.73%. To continue investigating profitability, this company’s Return on Assets is posted at 4.39, Equity is -2.07 and Total Capital is -0.5. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.01.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 4.65 points at the first support level, and at 4.53 for the second support level. However, for the 1st resistance point, the stock is sitting at 4.88, and for the 2nd resistance point, it is at 4.99.
CorMedix Inc [CRMD] reported earnings per share of -$0.26 for its fiscal quarter that ended on 12/30/2023. Based on the Wall Street analysts’ estimates, the company was expected to report earnings of -$0.2/share, meaning a difference of -$0.06 and a surprise factor of -30.00%. By comparison, the stated earnings for the previous quarter ended on 9/29/2023 were -$0.17 per share as compared to estimates of -$0.21 per share, a difference of $0.04 representing a surprise of 19.00%.
Ratios To Look Out For
It is important to note that CorMedix Inc [NASDAQ:CRMD] has a current ratio of 6.97. In addition, the Quick Ratio stands at 6.78 and the Cash Ratio stands at 6.95.
Transactions by insiders
Recent insider trading involved Todisco Joseph, Chief Executive Officer, that happened on Mar 13 ’24 when 13561.0 shares were purchased. Director, DUNTON ALAN W completed a deal on Dec 15 ’23 to buy 3000.0 shares. Meanwhile, Director DUNTON ALAN W bought 3000.0 shares on Dec 14 ’23.
